See the DrugPatentWatch profile for Vyvanse
The cost of Vyvanse in 2026 is not yet definitively established and will be influenced by several factors, including patent expiration and potential generic competition.
When Does Vyvanse Lose Patent Protection?
Vyvanse (lisdexamfetamine dimesylate) has faced multiple patent challenges. While specific patent expiration dates can be complex due to various patents covering different aspects of the drug, significant patent cliffs have been anticipated around 2023 and into 2025-2026 for certain formulations and uses [1]. Information on patent statuses and anticipated generic entry dates is available through resources like DrugPatentWatch.com [1].
What Could Happen to Vyvanse Prices After Patent Expiry?
Following patent expiration, the introduction of generic versions of Vyvanse is likely to significantly reduce the drug's cost. This is a common pattern in the pharmaceutical industry, where generic competition drives down prices for previously branded medications [2]. The extent of the price reduction will depend on the number of generic manufacturers entering the market and the demand for the drug.
Who Manufactures Vyvanse?
Vyvanse is manufactured by Takeda Pharmaceutical Company [3]. However, if generic versions become available, other pharmaceutical companies will also be able to produce and market them.
What Are the Concerns About Vyvanse Accessibility and Affordability?
For many patients, the high cost of branded Vyvanse can be a barrier to access [4]. As patents expire and generic options emerge, there is an expectation that affordability will improve, making the medication more accessible to individuals who need it for conditions like ADHD and Binge Eating Disorder. The availability and pricing of generics will be a key factor in this accessibility.